Zalicus receives royalty and milestone revenue from both Covidien/Mallinckrodt Inc. for the product Exalgo®, (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients,
and from Sanofi/Fovea Pharmaceuticals on the product candidate Prednisporin™/FOV1101, a topical ocular drug candidate containing low doses of the glucocorticoid, prednisolone acetate and the immunosuppressant cyclosporine A to treat inflammatory ocular diseases such as persistent allergic conjunctivitis.
